Inducible Nitric Oxide Synthase in Muscle Wasting Syndromes
Author Information
Author(s): Hall Derek T., Ma Jennifer F., Di Marco Sergio, Gallouzi Imed-Eddine
Primary Institution: McGill University, Biochemistry Department, Goodman Cancer Center, Montreal, Canada
Hypothesis
The review aims to elucidate the role of inducible nitric oxide synthase (iNOS) in muscle wasting syndromes such as sarcopenia and cachexia.
Conclusion
Targeting the iNOS/NO pathway may provide new therapeutic strategies for treating muscle wasting associated with sarcopenia and cachexia.
Supporting Evidence
- Muscle wasting is a serious affliction commonly found in aging individuals.
- Sarcopenia affects approximately 25% of individuals over the age of 64.
- Cachexia is characterized by a severe wasting of skeletal muscle tissue, often seen in chronic diseases.
- Inflammatory cytokines like TNFα and IL-6 are implicated in both sarcopenia and cachexia.
- iNOS has been shown to be an important mediator of TNFα-induced muscle loss.
Takeaway
As people age or suffer from diseases, they can lose muscle mass, which is called muscle wasting. This study looks at a specific enzyme, iNOS, that might help us find better treatments for this problem.
Methodology
This is a review article summarizing existing research on the role of iNOS in muscle wasting.
Limitations
The review does not present new experimental data but synthesizes existing literature.
Want to read the original?
Access the complete publication on the publisher's website